Fall 2025

Vertex Fall 2025 Co-op

Formulation

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$20 - $35/hr

+ Overtime Pay

No H1B Sponsorship

Boston, MA, USA

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • Pursuing M.S. or Ph.D in Chemical Engineering, Mechanical Engineering, Materials Engineering, Powder Mechanics
  • Experience in powder characterization
  • Demonstrating statistical principles and problem-solving
  • Ability to effectively communicate findings, progress, and problems
  • Ability to collaborate and work effectively in a multidisciplinary team
  • Strong organizational skills and high attention to detail
  • Legal authorization to work in the United States, now and in the future
  • Candidate must be enrolled in an advanced degree program if graduating before July 2025
  • Candidate must be available to work full-time, 40 hours per week from July - December 2025
Responsibilities
  • Use fundamental powder mechanics principles and process understanding to guide experimental design
  • Perform pilot scale tablet press experiments, and small-scale powder characterization tests
  • Identify and present relevant literature with the project team
  • Apply statistical principles and DoE approaches to guide process optimization
  • Analyze data, prepare presentations/reports, and present conclusions and recommendations
  • Contribute to fostering a collaborative working environment and positive team culture
Desired Qualifications
  • Experience using tablet press desired but not required
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself through its commitment to scientific innovation and strategic partnerships, allowing it to address unmet medical needs effectively. The company's goal is to improve the quality of life for patients with severe conditions by bringing transformative treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • EU approval for expanded cystic fibrosis treatment boosts market penetration in Europe.
  • Partnership with Arbor Biotechnologies opens new therapeutic areas and innovation opportunities.
  • Significant investments from firms indicate strong confidence in Vertex's growth potential.

What critics are saying

  • Increased competition in cystic fibrosis market may impact Vertex's market share.
  • Potential delays in EU clinical trials could affect new drug approval timelines.
  • Layoffs in Rhode Island suggest possible internal restructuring challenges or financial pressures.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on severe diseases with unmet medical needs, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's innovative cell therapies position it at the forefront of biotechnology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

PBN
Jun 10th, 2025
Vertex Pharmaceuticals to lay off 125 R.I. employees

PROVIDENCE - Vertex Pharmaceuticals Inc. is laying off 125 people in Rhode Island, according to a WARN notice filed with the R.I. Department of Labor and Training on June 8.

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).